FMOL Drug Shortage Memo: Intravenous Immune Globulin

August 1st, 2019

Dear Providers,

Intravenous Immune Globulin (IVIG) is on national backorder due to increased demand and manufacturer inability to meet this demand. All presentations are currently backordered or on allocation. The resolution date for the shortage is unknown at this time and all manufacturers are intermittently releasing product as it becomes available.

In an effort to conserve product for those patients with no alternatives, effective immediately, the pharmacy department will be reviewing all orders for IVIG to ensure they meet the P&T approved restriction criteria listed below. In addition, all adult IVIG orders will be dosed on ideal body weight or adjusted body weight where applicable. Pediatric IVIG orders will be dosed using actual body weight.

Thank you in advance for your assistance in ensuring our most critical patients receive appropriate therapy. For any questions, please contact the pharmacy department at your institution.

IVIG shall be dosed by <u>Ideal Body Weight</u> for adult patients. If patient is >20% of their ideal body weight, an adjusted body weight shall be used for dosing purposes.

Indication	Additional Required	Dose
	Criteria	
High Priority		
Autoimmune encephalitis	Neurology consult	1 gm/kg x 2
Guillain-Barre Syndrome	Neurology consult	1 gm/kg x 1
Myasthenia Gravis	Neurology consult	0.4 gm/kg/day x 5
		days OR
		2 gm/kg x 1
Idiopathic	Hematology consult	1 gm/kg x 1
Thrombocytopenia	AND Platelets < 20 and	
Purpura with Active	bleeding	
Bleeding		
Kawasaki Disease	None	2 gm/kg x 1
Primary immune	Immunology, Infectious	Not to exceed 0.6
deficiency (PID)	Disease, OR	gm/kg x 1
or hypogammaglobinemia	Hematology/Oncology	
with a recent IGG level	consult	



(within 6 months) < 400		
mg/dl Parvovirus B19	BMT or Hematology Consult AND Immunocompromised AND Hemoglobin < 8 without bleeding	1 gm/kg/day x 2 days
Solid Organ Transplant Antibody Mediated Rejection	None Inpatient and Outpatient	1 gm/kg x 2 days (may repeat for 2 additional days) Repeat 4 weeks after initial dose
Solid Organ Transplant Desensitization	Abdominal Transplant Team Consult	1 gm/kg x 2 days Repeat 2 weeks after initial dose
Solid Organ Transplant Parvovirus B19	Abdominal Transplant Team Consult	1 gm/kg/day x 2 days
Moderate Priority		
Bone Marrow Transplant	IgG < 400 mg/dL + recurrent sinopulmonary infections	0.4 gm/kg x 1
Chronic Lymphocytic Leukemia	IgG < 400 mg/dL AND Recurrent infections	0.4 gm/kg x 1
Idiopathic Thrombocytopenia Purpura without Active Bleeding and not Steroid Refractory	Hematology consult AND Platelets < 10	1 gm/kg x 1
Multiple Myeloma	IgG < 400 mg/dL AND Recurrent infections	0.4 gm/kg x 1
Parvovirus B19	Infectious Diseases Consult AND Immunocompromised AND Hemoglobin < 8 without bleeding	1 gm/kg/day x 2 days
Solid Organ Transplant Hypogammaglobulinemia	Lung Transplant Service Consult	0.5 gm/kg x 1



		I _
		For severe or
		recurrent infection:
		400 mg/kg every 21
		days as needed to
		keep serum IgG >
		700 mg/dL for
		duration of
		treatment
Solid Organ Transplant	Lung Transplant	0.5 gm/kg x 1
RSV Pneumonia	Service	0.5 giii/ kg x 1
Treatment with Ribavirin	Consult	
	Consuit	
therapy		
Low Priority		
BK Virus Associated		2 gm/kg IV x 1
Nephropathy		Alternative therapy:
		-Cidofovir
		-Foscarnet
- N		0 0 00
Bullous Diseases	Dermatology consult	2 gm/kg IV x 1 OR
	AND failed	1 gm/kg/day x 2
	corticosteroids	days
Chronic Inflammatory	None	1 gm/kg/day x 2
Demyelinating		days OR
Polyneuropathy		0.4 gm/kg/day x 5
Tolynear opacity		days
		uays
Encephalomyelitis Acute	Neurology consult AND	1 gm/kg/day x 2
Disseminated	Failed corticosteroids	days OR
		2 gm/kg x 1
Homolytic Discoss of the	Ago < 7 days	0 F am /lra v-1
Hemolytic Disease of the Newborn	Age < 7 days	0.5 gm/kg x1
Newborn	ABO incompatible with	(may repeat dose after 12h if
	mother	
	Severe, progressive	hyperbilirubinemia
	hyperbilirubinemia	worsening)
	despite at least 4 hours	
Idionathi-	phototherapy	1 cm /lvc 1
Idiopathic	Hematology consult	1 gm/kg x 1
Thrombocytopenia		Alternative Therapy:
Purpura without Active		-Rituximab
Bleeding AND Steroid		
Refractory		



Lambert Eaton Myasthenic Syndrome	None	1 gm/kg/day x 2 days OR 2 gm/kg x 1
Multifocal Motor Neuropathy	None	0.4 gm/kg/day x 5 days
Myocarditis	Pediatrics only Severe acute myocarditis	2 gm/kg x 1 given over 24 hours
Myopathies (refractory) - Dermatomyositis - Refractory polymyositis	Neurology consult AND Refractory to other therapies	1 gm/kg/day x 2 days OR 2 gm/kg x 1 OR 0.4 gm/kg/day x 5 days
Neonatal Alloimmune Thrombocytopenia	None	1 gm/kg/day x 2 days
RSV Pneumonia in Pediatric Immunocompromised Patients	None	0.5 gm/kg/day x 5 days PLUS ribavirin
Stevens-Johnson Syndrome OR Toxic Epidermal Necrolysis	Dermatology consult	1 gm/kg/day x 2 days
Toxic Shock Syndrome	Infectious Disease consult AND one of the following: Necrotizing fasciitis with streptococcal infection	1 gm/kg x 1 May give 0.5 gm/kg/day x 2 additional days
	Staphylococcal infection	

